Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
A TechRadar article noted that nearly 90% of enterprise information (documents, emails, videos) lies dormant in unstructured systems. This "dark data" isn't just neglected; it's a liability. GenAI ...
Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Protein function prediction is essential for elucidating biological processes and ...
For decades, enterprise data infrastructure focused on answering the question: “What happened in our business?” Business intelligence tools, data warehouses, and pipelines were built to surface ...
Abstract: Graph neural network is a new neural network model in recent years, whose advantage lies in processing graph structure data. In the era of big data, people can collect a large amount of ...
Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, ...
Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More As enterprises around the world double down on their AI projects, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results